Continued maintenance BCG might be considered in BCG-responsive patients with very high-risk NMIBC without adverse clinical and pathologic features. Rather than undergo upfront radical cystectomy, ...
Chemohyperthermia Safe, Effective for NMIBC Adjuvant Treatment Patients who received BCG induction within 3 weeks or 3 weeks or more after surgery for nonmuscle-invasive bladder cancer did not differ ...
After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...
The bacillus Calmette-Guérin (BCG) vaccine nearly halved the risk of progression among patients with non–muscle invasive bladder cancer (NMIBC) compared with transurethral resection of the bladder ...
(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a high-risk non-muscle invasive bladder cancer session and a presentation by Dr. Dingwei Ye discussing results of ...
SPARKS, NV / ACCESSWIRE / September 20, 2022 / (OTC PINK:LUDG) Ludwig Enterprises, a leading-edge innovator of genetic inflammatory biomarkers to diagnose and manage chronic diseases, is pleased to ...
rBCG offers an alternative to TICE® BCG amid U.S. shortages, impacting bladder cancer treatment availability. FDA's Expanded Access Program allows investigational rBCG use when no satisfactory ...
There are many reasons to have urology surgery. For example, your surgeon may operate to remove kidney stones, treat infertility, or manage urinary incontinence. Urologic surgeons treat patients of ...
Most systemic anticancer regimens combine drugs for increased efficacy, but this approach has rarely been applied to intravesicular treatment of bladder cancer. The current standard treatment for ...
The FDA approved nogapendekin alfa inbakicept (Anktiva) for bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC), the agency announced Monday. A first-in-class ...
ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results